Sha Huang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Sha Huang has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Luping Lin
Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital
7 shared publicationsHuaying Lai
Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital
6 shared publicationsGuangfeng Wu
Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital
5 shared publicationsJinfeng Lin
Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital
5 shared publicationsNingna Weng
Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital
5 shared publications- Xiao Chen
Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital
5 shared publications
Latest Publications
- Open Access
- 7 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1928835
Clinicopathologic characteristics and diagnostic value of PD-L1 in immune checkpoint inhibitor-related liver injury: a single-center retrospective study
Background and aims: Immune-mediated liver injury caused by checkpoint inhibitors (ILICI) differs from chemotherapy- or targeted drug-related hepatotoxicity in pathogenesis and management. Biomarkers to distinguish ILICI from other anticancer agent-induced liver injuries are lacking. We compared the clinicopathological features, treatments, and outcomes of ILICI versus other anticancer agent-related liver injuries to identify distinguishing biomarkers. Methods: We retrospectively included patients with liver injury during anticancer therapy at Fujian Cancer Hospital between June 2022 and November 2024. Cases were classified as ILICI or non-ILICI using the Common Terminology Criteria for Adverse Events v5.0 and the Roussel Uclaf Causality Assessment Method. Results: Sixty-seven patients were enrolled, including 30 ILICI and 37 non-ILICI. ILICI was associated with more high-grade liver injury than non-ILICI ( P = 0.001), with similar latency, recovery time, and prognosis. Corticosteroids were administered in 70% of ILICI vs. 5.4% of non-ILICI patients ( P < 0.001). Among 29 liver biopsies (19 ILICI, 10 non-ILICI), ILICI showed a higher focal necrosis score ( P = 0.031) and programmed death-ligand 1 (PD-L1) expression in liver sinusoidal endothelial cells (LSECs), lymphocytes, and Kupffer cells (KCs) ( P = 0.007). Receiver operating characteristic analysis showed that a PD-L1 positivity cutoff of >30% in LSECs, lymphocytes, and KCs discriminated ILICI with an AUC of 0.811 (95%CI: 0.641–0.980). Sensitivity analyses and Firth penalized logistic regression confirmed that this finding remained robust after adjustment for confounders including pre-biopsy corticosteroid use and inactive HBV carrier status. Conclusions: ILICI was associated with more severe hepatic inflammatory necrosis and a greater need for immunosuppressive therapy than non-ILICI. The PD-L1 positivity rate >30% in LSECs, lymphocytes, and KCs may serve as a potential diagnostic biomarker for ILICI.
- 7 October 2026
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 16, 1928835
Open AccessClinicopathologic characteristics and diagnostic value of PD-L1 in immune checkpoint inhibitor-related liver injury: a single-center retrospective study
Background and aims: Immune-mediated liver injury caused by checkpoint inhibitors (ILICI) differs from chemotherapy- or targeted drug-related hepatotoxicity in pathogenesis and management. Biomarkers to distinguish ILICI from other anticancer agent-induced liver injuries are lacking. We compared the clinicopathological features, treatments, and outcomes of ILICI versus other anticancer agent-related liver injuries to identify distinguishing biomarkers. Methods: We retrospectively included patients with liver injury during anticancer therapy at Fujian Cancer Hospital between June 2022 and November 2024. Cases were classified as ILICI or non-ILICI using the Common Terminology Criteria for Adverse Events v5.0 and the Roussel Uclaf Causality Assessment Method. Results: Sixty-seven patients were enrolled, including 30 ILICI and 37 non-ILICI. ILICI was associated with more high-grade liver injury than non-ILICI ( P = 0.001), with similar latency, recovery time, and prognosis. Corticosteroids were administered in 70% of ILICI vs. 5.4% of non-ILICI patients ( P < 0.001). Among 29 liver biopsies (19 ILICI, 10 non-ILICI), ILICI showed a higher focal necrosis score ( P = 0.031) and programmed death-ligand 1 (PD-L1) expression in liver sinusoidal endothelial cells (LSECs), lymphocytes, and Kupffer cells (KCs) ( P = 0.007). Receiver operating characteristic analysis showed that a PD-L1 positivity cutoff of >30% in LSECs, lymphocytes, and KCs discriminated ILICI with an AUC of 0.811 (95%CI: 0.641–0.980). Sensitivity analyses and Firth penalized logistic regression confirmed that this finding remained robust after adjustment for confounders including pre-biopsy corticosteroid use and inactive HBV carrier status. Conclusions: ILICI was associated with more severe hepatic inflammatory necrosis and a greater need for immunosuppressive therapy than non-ILICI. The PD-L1 positivity rate >30% in LSECs, lymphocytes, and KCs may serve as a potential diagnostic biomarker for ILICI.
- Open Access
- 6 October 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (10) , e0359327
Integrated multi-omic analysis characterizes an IFNγ-responsive-to-myeloid-suppressive immune continuum in immune-active hepatocellular carcinoma
Immune-active hepatocellular carcinoma (HCC) is commonly treated as a single inflamed phenotype, although its internal immune heterogeneity remains incompletely defined. We integrated public bulk transcriptomic, single-cell, spatial transcriptomic, proteomic, phosphoproteomic, and treatment-cohort data to test whether this heterogeneity is better represented by discrete states or a continuous immune axis. In 112 checkpoint-high TCGA-LIHC tumors, an inflamed-minus-myeloid axis showed structured heterogeneity but no robust empirical bimodality: the observed kernel-density curve had one prominent mode and none of 1,000 bootstrap resamples contained two or more prominent modes. IFNγ-responsive-associated and myeloid-suppressive-associated labels were therefore retained only as operational summaries of opposing axis tendencies, and the biological polarity persisted across alternative definitions of immune-active entry. A fixed 10-gene within-sample rank template-contrast score transferred the axis to independent HCC cohorts. Transcriptomic analyses based on gene sets non-overlapping with the compact panel and original state-defining genes supported the IFNγ-oriented end, whereas spatial analyses showed local cross-end coexistence with reduced immediate-neighbor mixing relative to a count-preserving random-label null, and paired proteomic/phosphoproteomic analyses showed concordant myeloid-oriented associations involving macrophage, fibroblast/extracellular-matrix, hypoxia, SPP1-integrin-FAK, and myeloid-receptor programs. Direct application of the frozen transfer score to four public HCC immunotherapy cohorts yielded heterogeneous, imprecise response associations (pooled Hedges’ g = 0.10, 95% CI −0.42 to 0.61) and did not establish clinical response prediction. These results support a structured IFNγ-responsive-to-myeloid-suppressive continuum within immune-active HCC. The framework is transferable across public datasets but requires prospective HCC-specific clinical validation, while functional perturbation studies are needed before causal or therapeutic claims.
- 6 October 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (10) , e0359327
Open AccessIntegrated multi-omic analysis characterizes an IFNγ-responsive-to-myeloid-suppressive immune continuum in immune-active hepatocellular carcinoma
Immune-active hepatocellular carcinoma (HCC) is commonly treated as a single inflamed phenotype, although its internal immune heterogeneity remains incompletely defined. We integrated public bulk transcriptomic, single-cell, spatial transcriptomic, proteomic, phosphoproteomic, and treatment-cohort data to test whether this heterogeneity is better represented by discrete states or a continuous immune axis. In 112 checkpoint-high TCGA-LIHC tumors, an inflamed-minus-myeloid axis showed structured heterogeneity but no robust empirical bimodality: the observed kernel-density curve had one prominent mode and none of 1,000 bootstrap resamples contained two or more prominent modes. IFNγ-responsive-associated and myeloid-suppressive-associated labels were therefore retained only as operational summaries of opposing axis tendencies, and the biological polarity persisted across alternative definitions of immune-active entry. A fixed 10-gene within-sample rank template-contrast score transferred the axis to independent HCC cohorts. Transcriptomic analyses based on gene sets non-overlapping with the compact panel and original state-defining genes supported the IFNγ-oriented end, whereas spatial analyses showed local cross-end coexistence with reduced immediate-neighbor mixing relative to a count-preserving random-label null, and paired proteomic/phosphoproteomic analyses showed concordant myeloid-oriented associations involving macrophage, fibroblast/extracellular-matrix, hypoxia, SPP1-integrin-FAK, and myeloid-receptor programs. Direct application of the frozen transfer score to four public HCC immunotherapy cohorts yielded heterogeneous, imprecise response associations (pooled Hedges’ g = 0.10, 95% CI −0.42 to 0.61) and did not establish clinical response prediction. These results support a structured IFNγ-responsive-to-myeloid-suppressive continuum within immune-active HCC. The framework is transferable across public datasets but requires prospective HCC-specific clinical validation, while functional perturbation studies are needed before causal or therapeutic claims.
- Open Access
- 9 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1714472
Identification of plasma lipidomic biomarkers for prognostic stratification in advanced gastric cancer treated with PD-1 inhibitor plus chemotherapy
Background: Immunotherapy combined with chemotherapy has improved outcomes in advanced gastric cancer (GC), but reliable biomarkers to predict clinical benefit remain limited. Metabolomics provides a comprehensive assessment of systemic metabolic changes and may yield prognostic indicators to guide treatment selection. Methods: We performed untargeted liquid chromatography–tandem mass spectrometry (LC-MS/MS) metabolomics on baseline plasma from 40 patients with advanced GC receiving first-line programmed cell death protein-1 (PD-1) inhibitor plus chemotherapy. Patients were stratified into long-term survivors (LTS) and short-term survivors (STS) based on median overall survival (OS). Differential metabolites were identified using multivariate statistics, followed by univariate Cox regression and least absolute shrinkage and selection operator (LASSO) analysis to construct a metabolite-based risk score. Prognostic performance was evaluated using Kaplan-Meier analysis, time-dependent receiver operating characteristic (ROC) curves, and multivariate Cox models. Comparisons with conventional clinical factors were conducted, and a prognostic nomogram was developed. Proportional-hazards assumptions were assessed with Schoenfeld residuals; discrimination was optimism-corrected using 1,000-bootstrap resampling; Harrell’s concordance index (C-index), time-dependent area under the curve (AUC), and bootstrap-corrected calibration curves were reported. Twelve-month decision-curve analysis (DCA) quantified net clinical benefit compared with clinicopathologic baselines. Results: A total of 4,298 metabolites were detected, including 830 Level 1 and 1,321 Level 2 identifications. Principal component analysis and orthogonal partial least squares discriminant analysis showed clear separation between LTS and STS groups. Differential analysis revealed metabolites enriched in bile acid, amino acid, and retinol metabolism pathways. Cox and LASSO analyses identified six independent prognostic metabolites. The resulting metabolite-based risk score significantly stratified OS and progression-free survival ( p < 0.01) and demonstrated stable predictive accuracy over 6–24 months. Compared with age, sex, tumor grade, and programmed death-ligand 1 combined positive score (PD-L1 CPS), the risk score showed superior discrimination. A nomogram integrating risk score, grade, and PD-L1 CPS yielded accurate OS predictions with strong calibration and higher net benefit in DCA. Internal validation supports the robustness of findings within this single-center, 40-patient cohort. Conclusions: A plasma metabolite-based risk score derived from six biomarkers independently predicts survival in advanced GC treated with PD-1–based immunotherapy and offers a practical tool for individualized prognosis.
- 9 February 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1714472
Open AccessIdentification of plasma lipidomic biomarkers for prognostic stratification in advanced gastric cancer treated with PD-1 inhibitor plus chemotherapy
Background: Immunotherapy combined with chemotherapy has improved outcomes in advanced gastric cancer (GC), but reliable biomarkers to predict clinical benefit remain limited. Metabolomics provides a comprehensive assessment of systemic metabolic changes and may yield prognostic indicators to guide treatment selection. Methods: We performed untargeted liquid chromatography–tandem mass spectrometry (LC-MS/MS) metabolomics on baseline plasma from 40 patients with advanced GC receiving first-line programmed cell death protein-1 (PD-1) inhibitor plus chemotherapy. Patients were stratified into long-term survivors (LTS) and short-term survivors (STS) based on median overall survival (OS). Differential metabolites were identified using multivariate statistics, followed by univariate Cox regression and least absolute shrinkage and selection operator (LASSO) analysis to construct a metabolite-based risk score. Prognostic performance was evaluated using Kaplan-Meier analysis, time-dependent receiver operating characteristic (ROC) curves, and multivariate Cox models. Comparisons with conventional clinical factors were conducted, and a prognostic nomogram was developed. Proportional-hazards assumptions were assessed with Schoenfeld residuals; discrimination was optimism-corrected using 1,000-bootstrap resampling; Harrell’s concordance index (C-index), time-dependent area under the curve (AUC), and bootstrap-corrected calibration curves were reported. Twelve-month decision-curve analysis (DCA) quantified net clinical benefit compared with clinicopathologic baselines. Results: A total of 4,298 metabolites were detected, including 830 Level 1 and 1,321 Level 2 identifications. Principal component analysis and orthogonal partial least squares discriminant analysis showed clear separation between LTS and STS groups. Differential analysis revealed metabolites enriched in bile acid, amino acid, and retinol metabolism pathways. Cox and LASSO analyses identified six independent prognostic metabolites. The resulting metabolite-based risk score significantly stratified OS and progression-free survival ( p < 0.01) and demonstrated stable predictive accuracy over 6–24 months. Compared with age, sex, tumor grade, and programmed death-ligand 1 combined positive score (PD-L1 CPS), the risk score showed superior discrimination. A nomogram integrating risk score, grade, and PD-L1 CPS yielded accurate OS predictions with strong calibration and higher net benefit in DCA. Internal validation supports the robustness of findings within this single-center, 40-patient cohort. Conclusions: A plasma metabolite-based risk score derived from six biomarkers independently predicts survival in advanced GC treated with PD-1–based immunotherapy and offers a practical tool for individualized prognosis.
- Open Access
- 22 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1788767
Correction: Global assessment of hepatic safety in novel immunotherapies: a systematic review and meta-analysis
• Please read through all the templates before choosing • Pick the most relevant text template(s) from the following page and delete all others. • Edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. • Please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary • Submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example:There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.The original version of this article has been updated. Changing author order The order of authors in the author list of the published paper was erroneously given as: [Minyan Ye 1 , Yinuo Dong 2 , Xiaoyun Li 2,3 , Yang Zhi 2 , Yuping Lu 1 , Jieting Tang 2 , Wei Zhong 2 , Xiaohong Lei 2 , Yanyan Song 4 * , Sha Huang 1 * and Yimin Mao 2 * ] The correct author list reads: [Minyan Ye 1 , Yinuo Dong 2 , Xiaoyun Li 2,3 , Yang Zhi 2 , Yuping Lu 1 , Jieting Tang 2 , Wei Zhong 2 , Xiaohong Lei 2 , Yimin Mao 2 * , Sha Huang 1 * and Yanyan Song 4 * ] The original version of this article has been updated. The original version of this article has been updated.
- 22 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 17, 1788767
Open AccessCorrection: Global assessment of hepatic safety in novel immunotherapies: a systematic review and meta-analysis
• Please read through all the templates before choosing • Pick the most relevant text template(s) from the following page and delete all others. • Edit the text as necessary, ensuring that the original incorrect text is included for the record, please see the below. • Please do not use any extra formatting when editing the templates, and only modify the red text unless absolutely necessary • Submit to Frontiers following the instructions on this page.When the original text contained incorrect information, to preserve the scientific record, please include that text when editing the below templates. For example:There was a mistake in the Funding statement, an incorrect number was used. The correct number is "2015C03Bd051.". The publisher apologizes for this mistake.The original version of this article has been updated. Changing author order The order of authors in the author list of the published paper was erroneously given as: [Minyan Ye 1 , Yinuo Dong 2 , Xiaoyun Li 2,3 , Yang Zhi 2 , Yuping Lu 1 , Jieting Tang 2 , Wei Zhong 2 , Xiaohong Lei 2 , Yanyan Song 4 * , Sha Huang 1 * and Yimin Mao 2 * ] The correct author list reads: [Minyan Ye 1 , Yinuo Dong 2 , Xiaoyun Li 2,3 , Yang Zhi 2 , Yuping Lu 1 , Jieting Tang 2 , Wei Zhong 2 , Xiaohong Lei 2 , Yimin Mao 2 * , Sha Huang 1 * and Yanyan Song 4 * ] The original version of this article has been updated. The original version of this article has been updated.
- Open Access
- 12 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1677998
Global assessment of hepatic safety in novel immunotherapies: a systematic review and meta-analysis
Background: This study explored whether integrating innovative immunotherapies targeting costimulatory or co-inhibitory pathways beyond standard PD-1, PD-L1, and CTLA-4 treatments affects hepatic adverse events. We further analyzed liver-related side effects in patients with cancer receiving these novel therapies alone or in combination with others. Methods: Clinical studies on immunotherapies targeting molecules such as LAG-3, TIGIT, TIM-3, VISTA, CD47, ICOS, CD40, and B7-H3 were retrieved from PubMed, Embase, Cochrane Library, and Web of Science. Data from eligible studies that reported liver-related adverse events until May 2024 were included. Results: This analysis included 63 studies involving 7,327 patients. Among these, randomized controlled trials demonstrated that adding LAG-3 or TIGIT inhibitors to established therapies did not increase the risk of elevated hepatic enzyme levels or hepatitis. CD27-CD70-targeted monotherapy showed a strong association with elevated transaminase levels. Dual therapies combining 4-1BB agonists with PD-1/PD-L1 inhibitors resulted in >15% all-grade transaminase elevation, whereas CD40 agonists paired with immunotherapy resulted in >4% high-grade elevations. Immunotherapy-chemotherapy combinations showed high transaminase elevation rates. Overall, the incidence of elevated liver enzyme levels was similar between the single-agent and dual immunotherapy groups. The addition of chemotherapy or targeted therapy to single-agent immunotherapy increases the incidence of adverse events associated with elevated liver enzyme levels. The incidence of liver enzyme adverse events continued to increase with the addition of immunotherapy to the combination regimens. Cholestatic enzyme elevations were prominent in CD27-CD70 monotherapy and CD40 agonist combinations. Conclusions: This meta-analysis suggests adding LAG-3 or TIGIT inhibitors to existing therapies may not significantly increase hepatic toxicity. It reviewed adverse events from novel immunotherapies alone or combined with PD-1/PD-L1/CTLA-4 inhibitors, targeted agents, or chemotherapy. These findings have important clinical implications.
- 12 January 2026
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1677998
Open AccessGlobal assessment of hepatic safety in novel immunotherapies: a systematic review and meta-analysis
Background: This study explored whether integrating innovative immunotherapies targeting costimulatory or co-inhibitory pathways beyond standard PD-1, PD-L1, and CTLA-4 treatments affects hepatic adverse events. We further analyzed liver-related side effects in patients with cancer receiving these novel therapies alone or in combination with others. Methods: Clinical studies on immunotherapies targeting molecules such as LAG-3, TIGIT, TIM-3, VISTA, CD47, ICOS, CD40, and B7-H3 were retrieved from PubMed, Embase, Cochrane Library, and Web of Science. Data from eligible studies that reported liver-related adverse events until May 2024 were included. Results: This analysis included 63 studies involving 7,327 patients. Among these, randomized controlled trials demonstrated that adding LAG-3 or TIGIT inhibitors to established therapies did not increase the risk of elevated hepatic enzyme levels or hepatitis. CD27-CD70-targeted monotherapy showed a strong association with elevated transaminase levels. Dual therapies combining 4-1BB agonists with PD-1/PD-L1 inhibitors resulted in >15% all-grade transaminase elevation, whereas CD40 agonists paired with immunotherapy resulted in >4% high-grade elevations. Immunotherapy-chemotherapy combinations showed high transaminase elevation rates. Overall, the incidence of elevated liver enzyme levels was similar between the single-agent and dual immunotherapy groups. The addition of chemotherapy or targeted therapy to single-agent immunotherapy increases the incidence of adverse events associated with elevated liver enzyme levels. The incidence of liver enzyme adverse events continued to increase with the addition of immunotherapy to the combination regimens. Cholestatic enzyme elevations were prominent in CD27-CD70 monotherapy and CD40 agonist combinations. Conclusions: This meta-analysis suggests adding LAG-3 or TIGIT inhibitors to existing therapies may not significantly increase hepatic toxicity. It reviewed adverse events from novel immunotherapies alone or combined with PD-1/PD-L1/CTLA-4 inhibitors, targeted agents, or chemotherapy. These findings have important clinical implications.
- Open Access
- 29 May 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (5) , e0323023
Hepatotoxicity of ICI monotherapy or combination therapy in HCC: A systematic review and meta-analysis
Background: The aim of this study was to reveal the hepatotoxicity profile of different immune checkpoint inhibitor (ICI) used strategies in patients with Hepatocellular carcinoma (HCC) by meta-analysis. Methods: Literature was searched through PubMed, Cochrane, Embase, and Web of Science up to October 14, 2023, and the subject terms were “Carcinoma, Hepatocellular” and “Immune Checkpoint Inhibitors”. The main observations were alanine aminotransferase (ALT) and aspartate aminotransferase (AST). ALT and AST were graded according to CTCAE. Results: A total of 32 studies with 7662 patients were included in the analysis. The results of meta-analysis showed that among different ICI treatment regimens, ICI monotherapy had the lowest incidence of any grade of ALT and AST elevation, and the highest for ICI+multikinase inhibitor (MKI); ICI+anti-VEGFR/VEGFA and ICI monotherapy had a lower incidence of grade ≥3 ALT and AST elevations, while ICI + MKI, dual immunotherapy, and dual immunotherapy+MKI had a higher incidence of grade ≥3 ALT and AST elevations; ICI monotherapy was more prone to any grade ALT elevation than placebo, and ICI monotherapy was more prone to ≥ 3 grade AST elevation than MKI; combination immunotherapy was more prone than MKI to any grade ALT and AST elevations; in grade ≥3 ALT and AST elevations, combination immunotherapy was similar to ICI monotherapy and MKI; ICI + MKI was more likely to have grade ≥3 ALT. Conclusion: ICI monotherapy was more likely to cause severe hepatotoxicity than MKI. Combination immunotherapy treatment increased the incidence of hepatotoxicity compared to monotherapy, and ICI + MKI was prone to develop severe hepatotoxicity.
- 29 May 2025
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 20 (5) , e0323023
Open AccessHepatotoxicity of ICI monotherapy or combination therapy in HCC: A systematic review and meta-analysis
Background: The aim of this study was to reveal the hepatotoxicity profile of different immune checkpoint inhibitor (ICI) used strategies in patients with Hepatocellular carcinoma (HCC) by meta-analysis. Methods: Literature was searched through PubMed, Cochrane, Embase, and Web of Science up to October 14, 2023, and the subject terms were “Carcinoma, Hepatocellular” and “Immune Checkpoint Inhibitors”. The main observations were alanine aminotransferase (ALT) and aspartate aminotransferase (AST). ALT and AST were graded according to CTCAE. Results: A total of 32 studies with 7662 patients were included in the analysis. The results of meta-analysis showed that among different ICI treatment regimens, ICI monotherapy had the lowest incidence of any grade of ALT and AST elevation, and the highest for ICI+multikinase inhibitor (MKI); ICI+anti-VEGFR/VEGFA and ICI monotherapy had a lower incidence of grade ≥3 ALT and AST elevations, while ICI + MKI, dual immunotherapy, and dual immunotherapy+MKI had a higher incidence of grade ≥3 ALT and AST elevations; ICI monotherapy was more prone to any grade ALT elevation than placebo, and ICI monotherapy was more prone to ≥ 3 grade AST elevation than MKI; combination immunotherapy was more prone than MKI to any grade ALT and AST elevations; in grade ≥3 ALT and AST elevations, combination immunotherapy was similar to ICI monotherapy and MKI; ICI + MKI was more likely to have grade ≥3 ALT. Conclusion: ICI monotherapy was more likely to cause severe hepatotoxicity than MKI. Combination immunotherapy treatment increased the incidence of hepatotoxicity compared to monotherapy, and ICI + MKI was prone to develop severe hepatotoxicity.